Upadacitinib治疗生物制剂难治性银屑病关节炎:SELECT-PsA 2
SELECT-PsA 2是一项24周随机、安慰剂对照、双盲3期试验,纳入642例对至少一种生物制剂DMARD应答不足或不耐受的活动性PsA患者。第12周Upadacitinib 15 mg和30 mg组ACR20应答率分别为56.9%和63.8%,显著高于安慰剂组24.1%(p<0.001);第24周MDA达成率分别为25.1%和28.9%,安慰剂组2.8%(p<0.001)。
要点
- 对生物制剂DMARD应答不足或不耐受的活动性PsA患者,Upadacitinib 15 mg和30 mg在12周ACR20上均优于安慰剂。
- 第24周MDA达成率Upadacitinib 15 mg为25.1%、30 mg为28.9%,均显著高于安慰剂2.8%。
- 严重感染率安慰剂0.5%、Upadacitinib 15 mg 0.5%、30 mg 2.8%,30 mg组总体不良事件率更高。
核心结论
- 对至少一种生物制剂DMARD应答不足或不耐受的活动性PsA患者,Upadacitinib 15 mg和30 mg在24周内改善PsA症状和体征优于安慰剂。
研究设计与样本
- 24周随机、安慰剂对照、双盲3期试验,642例患者按2:2:1:1随机分配至Upadacitinib 15 mg或30 mg每日一次、安慰剂后第24周换用Upadacitinib 15 mg或30 mg。
- 主要终点为第12周ACR20应答率,第24周评估MDA,安全性报告纳入所有至少接受一剂试验药物的患者。
主要发现
- 第12周ACR20应答率:Upadacitinib 15 mg组56.9%、30 mg组63.8%,安慰剂组24.1%,两项比较p<0.001。
- 第24周MDA达成率:Upadacitinib 15 mg组25.1%、30 mg组28.9%,安慰剂组2.8%,两项比较p<0.001。
- 第24周治疗中出现的不良事件率安慰剂与Upadacitinib 15 mg相似,30 mg组更高;严重感染率分别为0.5%、0.5%和2.8%。
关键数值与推荐
- 主要终点为第12周ACR20应答率,第24周评估MDA。
- 第12周ACR20:Upadacitinib 15 mg 56.9%、30 mg 63.8% vs 安慰剂24.1%(p<0.001)。
- 第24周MDA:Upadacitinib 15 mg 25.1%、30 mg 28.9% vs 安慰剂2.8%(p<0.001)。
- 严重感染率:安慰剂0.5%、Upadacitinib 15 mg 0.5%、30 mg 2.8%。
临床怎么用
- 对至少一种生物制剂DMARD应答不足或不耐受的活动性PsA患者,可考虑Upadacitinib 15 mg或30 mg每日一次治疗。
- 选择30 mg剂量时需关注其更高的总体不良事件率和严重感染率。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD). METHODS: In this 24-week randomised, placebo-controlled, double-blind, phase 3 trial, 642 patients were randomised (2:2:1:1) to once per day upadacitinib 15 mg or 30 mg, placebo followed by upadacitinib 15 mg or placebo followed by upadacitinib 30 mg at week 24. The primary endpoint was the proportion of patients achieving American College of Rheumatology (ACR) 20 response at week 12. Achievement of minimal disease activity (MDA) was assessed at week 24. Treatment-emergent adverse events are reported for all patients who received at least one dose of trial drug. RESULTS: At week 12, significantly more patients receiving upadacitinib 15 mg and 30 mg versus placebo achieved ACR20 (56.9% and 63.8% vs 24.1%; p<0.001 for both comparisons). At week 24, MDA was achieved by more upadacitinib 15 mg-treated (25.1%) and 30 mg-treated patients (28.9%) versus placebo (2.8%; p<0.001 for both comparisons). Generally, the rates of treatment-emergent adverse events were similar with placebo and upadacitinib 15 mg and higher with upadacitinib 30 mg at week 24. Rates of serious infections were 0.5%, 0.5% and 2.8% with placebo, upadacitinib 15 mg and upadacitinib 30 mg, respectively. CONCLUSION: In this trial of patients with active PsA who had inadequate response or intolerance to at least one biologic DMARD, upadacitinib 15 mg and 30 mg was more effective than placebo over 24 weeks in improving signs and symptoms of PsA. CLINICAL TRIAL REGISTRATION NUMBER: NCT03104374.
引用
- Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020. PMID: 33272960. doi:10.1136/annrheumdis-2020-218870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。